期刊
BONE MARROW TRANSPLANTATION
卷 44, 期 12, 页码 769-777出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2009.300
关键词
AML; relapse; transplantation; DLI
Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2-20% patients receive a second allo-SCT), and efforts to increase the number of patients who may benefit from a second allo-SCT are ongoing. In addition, understanding the varied biological processes that are operative in disease relapse has encouraged the development of novel therapies, and could be beneficial to patients who are currently managed conservatively with supportive care for relapsed disease. Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, we discuss the currently available approaches for relapsed AML after allo-SCT. Bone Marrow Transplantation (2009) 44, 769-777; doi: 10.1038/bmt.2009.300; published online 26 October 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据